A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs PRX 003 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Prothena
  • Most Recent Events

    • 08 Aug 2017 According to a Prothena media release, top-line results from this trial are expected in October 2017.
    • 05 Jul 2016 According to Prothena Corporation media release, interim data expected by mid-2017.
    • 03 May 2016 According to a Prothena media release, topline results from this trial are expected in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top